StocksFundsScreenerSectorsWatchlists
BTAI

BTAI - Bioxcel Therapeutics Inc Stock Price, Fair Value and News

2.87USD-0.01 (-0.35%)Delayed as of 28 Mar 2024, 11:59 am ET

Market Summary

BTAI
USD2.87-0.01
Delayedas of 28 Mar 2024, 11:59 am
-0.35%

BTAI Stock Price

View Fullscreen

BTAI RSI Chart

BTAI Valuation

Market Cap

84.1M

Price/Earnings (Trailing)

-0.47

Price/Sales (Trailing)

60.94

Price/Free Cashflow

-0.54

BTAI Price/Sales (Trailing)

BTAI Profitability

Return on Equity

316.86%

Return on Assets

-242.94%

Free Cashflow Yield

-184.33%

BTAI Fundamentals

BTAI Revenue

Revenue (TTM)

1.4M

Rev. Growth (Yr)

119.24%

Rev. Growth (Qtr)

10.26%

BTAI Earnings

Earnings (TTM)

-179.1M

Earnings Growth (Yr)

59.39%

Earnings Growth (Qtr)

55.92%

Breaking Down BTAI Revenue

52 Week Range

2.3429.56
(Low)(High)

Last 7 days

4.9%

Last 30 days

-19.9%

Last 90 days

-7.3%

Trailing 12 Months

-87.0%

How does BTAI drawdown profile look like?

BTAI Financial Health

Current Ratio

2.65

Debt/Equity

-1.75

Debt/Cashflow

-1.56

BTAI Investor Care

Shares Dilution (1Y)

6.33%

Diluted EPS (TTM)

-6.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023626.3K877.5K1.1M1.4M
2022000375.0K

Tracking the Latest Insider Buys and Sells of Bioxcel Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 14, 2023
yocca frank
acquired
-
-
521
chief scientific officer
Dec 14, 2023
steinhart richard i
acquired
-
-
521
chief financial officer
Dec 14, 2023
o'neill vincent
acquired
-
-
521
chief medical officer
Dec 14, 2023
mehta vimal
acquired
-
-
2,609
ceo and president
Dec 14, 2023
rodriguez javier
acquired
-
-
521
see remarks
Sep 14, 2023
yocca frank
acquired
-
-
521
chief scientific officer
Sep 14, 2023
steinhart richard i
acquired
-
-
521
chief financial officer
Sep 14, 2023
o'neill vincent
acquired
-
-
521
chief medical officer
Sep 14, 2023
mehta vimal
acquired
-
-
2,610
ceo and president
Sep 14, 2023
rodriguez javier
acquired
-
-
521
see remarks

1–10 of 50

Which funds bought or sold BTAI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
2,764
2,764
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-10.74
125,974
3,213,920
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
reduced
-71.1
-222,891
113,280
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.41
4,129
29,745
-%
Feb 26, 2024
Virtu Financial LLC
new
-
176,000
176,000
0.01%
Feb 15, 2024
BARCLAYS PLC
added
264
64,000
82,000
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-77.5
-24,938
8,913
-%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-78.09
-266,861
91,577
-%
Feb 15, 2024
Virtus ETF Advisers LLC
sold off
-100
-11,754
-
-%
Feb 14, 2024
MARSHALL WACE, LLP
sold off
-100
-71,359
-
-%

1–10 of 42

Are Funds Buying or Selling BTAI?

Are funds buying BTAI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BTAI
No. of Funds

Unveiling Bioxcel Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
1.55%
465,381
SC 13G/A
Oct 19, 2023
bioxcel holdings, inc.
30.1%
8,901,750
SC 13G/A
Oct 13, 2023
fmr llc
-
0
SC 13G/A
Oct 10, 2023
fil ltd
-
0
SC 13G/A
Sep 28, 2023
bioxcel llc
29.2%
8,546,750
SC 13D
Apr 04, 2023
bioxcel holdings, inc.
29.5%
8,546,750
SC 13G/A
Feb 14, 2023
bioxcel holdings, inc.
30.5%
8,546,750
SC 13G/A
Feb 14, 2023
alliancebernstein l.p.
0.1%
24,000
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A

Recent SEC filings of Bioxcel Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 25, 2024
8-K
Current Report
Mar 25, 2024
424B5
Prospectus Filed
Mar 22, 2024
10-K
Annual Report
Mar 12, 2024
8-K
Current Report
Feb 14, 2024
8-K
Current Report
Feb 12, 2024
8-K
Current Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
8-K
Current Report
Feb 08, 2024
8-K
Current Report
Feb 08, 2024
424B5
Prospectus Filed

Peers (Alternatives to Bioxcel Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Bioxcel Therapeutics Inc News

Latest updates
MarketBeat26 Mar 202402:40 am
InvestorPlace09 Feb 202408:00 am

Bioxcel Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q3
Revenue10.3%376341457206172137
Costs and Expenses-58.4%20,25048,63852,87151,40453,12939,127
  S&GA Expenses-60.6%9,60324,34425,87223,59520,53417,054
  R&D Expenses-49.4%9,93419,61926,97327,80032,58622,062
Interest Expenses5.6%3,4363,2523,2593,3672,9203,700
Net Income55.9%-22,256-50,486-53,515-52,796-54,808-41,805
Net Income Margin30.8%-129.75*-187.47*-231.25*-298.73*-442.02*-
Free Cashflow28.5%-26,863-37,584-38,206-52,353-38,639-31,186
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-26.6%74.0010014018020624524821123926128120022023970.0086.0036.0044.0034.0040.0044.00
  Current Assets-26.9%72.0099.0013817720324224520823725727719721723668.0084.0034.0041.0032.0038.0043.00
    Cash Equivalents-27.5%65.0090.0012816619423223320023325327319421323365.0080.0032.0040.0030.0036.0043.00
  Inventory-1.3%2.002.002.002.002.001.001.001.00-------------
  Net PPE-9.0%1.001.001.001.001.001.001.001.001.001.001.002.001.001.001.001.001.001.001.001.000.00
Liabilities-7.7%13014113412712911884.0017.0018.0016.0014.0014.0013.0018.0017.0013.009.009.009.008.005.00
  Current Liabilities-30.8%27.0039.0035.0029.0033.0023.0020.0016.0017.0015.0012.0012.0012.0016.0016.0012.008.008.008.007.005.00
  Long Term Debt-100.0%-99.0097.0095.0093.0092.0061.00--------------
    LT Debt, Non Current1.5%10199.0097.0095.0093.0092.0061.00--------------
Shareholder's Equity-Infinity%-56.51-6.0053.0077.0012716419422224626718720722153.0073.0027.0034.0025.0032.0039.00
  Retained Earnings-3.9%-590-568-517-464-411-356-314-277-245-219-192-165-138-117-93.02-71.60-56.69-48.41-39.40-30.92-23.72
  Additional Paid-In Capital1.2%53452852451748848447947146746546035234633914614484.0083.0065.0063.0063.00
Shares Outstanding2.2%30.0029.0029.0029.0028.0028.0028.0028.0028.0026.0025.0025.00---------
Float-------251---551---565---63.00--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations28.5%-26,863-37,584-38,206-52,353-38,639-31,186-33,103-32,413-19,932-20,199-22,382-19,640-20,272-19,101-14,820-12,157-7,919-7,485-6,027-5,670-4,341
  Share Based Compensation-10.3%3,5994,0146,1244,8774,5474,4834,4823,8252,2364,8856,7695,5656,6115,2681,9567766547761,030682133
Cashflow From Investing--------19.00-120-12.00-17.00-100-316-2705.00-35.00-16.00-2.00-43.00-225-600-
Cashflow From Financing-2,123-25024,14950.0030,048---71.00101,524852233187,02927159,82695.0017,815-79.001.00-58.00
  Buy Backs----------------9,024-----

BTAI Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues  
Product revenue, net$ 1,380$ 375
Operating expenses  
Cost of goods sold1,26020
Research and development84,32691,239
Selling, general and administrative83,41368,761
Restructuring costs4,163 
Total operating expenses173,162160,020
Loss from operations(171,782)(159,645)
Other expense (income)  
Interest expense13,3148,213
Interest income(5,649)(2,528)
Other (income) expense, net(394)427
Net loss$ (179,053)$ (165,757)
Basic net loss per share attributable to common stockholders (in dollars per share)$ (6.15)$ (5.92)
Diluted net loss per share attributable to common stockholders (in dollars per share)$ (6.15)$ (5.92)
Weighted average shares outstanding - basic (in shares)29,12928,015
Weighted average shares outstanding - diluted (in shares)29,12928,015

BTAI Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 65,221$ 193,725
Accounts receivable, net71248
Inventory1,9911,985
Prepaid expenses2,7823,067
Other current assets2,0783,843
Total current assets72,143202,868
Property and equipment, net7841,084
Operating lease right-of-use assets688976
Other assets87925
Total assets73,702205,853
Current liabilities  
Accounts payable13,65410,228
Accrued expenses12,42418,669
Accrued interest7363,175
Total current liabilities27,26732,898
Long-term portion of operating lease liabilities440786
Derivative liabilities1,9052,343
Long-term debt100,59893,051
Total liabilities130,210129,078
Commitments and contingencies (Note 18)
Stockholders' (deficit) equity  
Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022
Common stock, $0.001 par value, 100,000 shares authorized as of December 31, 2023 and December 31, 2022; 29,930 and 28,147 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively3028
Additional paid-in-capital534,060488,292
Accumulated deficit(590,598)(411,545)
Total stockholders' (deficit) equity(56,508)76,775
Total liabilities and stockholders' (deficit) equity73,702205,853
Related Party  
Current liabilities  
Other current liabilities107422
Nonrelated Party  
Current liabilities  
Other current liabilities$ 346$ 404
BTAI
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
 CEO
 WEBSITEwww.bioxceltherapeutics.com
 EMPLOYEES183

Bioxcel Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Bioxcel Therapeutics Inc? What does BTAI stand for in stocks?

BTAI is the stock ticker symbol of Bioxcel Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bioxcel Therapeutics Inc (BTAI)?

As of Wed Mar 27 2024, market cap of Bioxcel Therapeutics Inc is 84.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BTAI stock?

You can check BTAI's fair value in chart for subscribers.

What is the fair value of BTAI stock?

You can check BTAI's fair value in chart for subscribers. The fair value of Bioxcel Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bioxcel Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BTAI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bioxcel Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BTAI is over valued or under valued. Whether Bioxcel Therapeutics Inc is cheap or expensive depends on the assumptions which impact Bioxcel Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BTAI.

What is Bioxcel Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, BTAI's PE ratio (Price to Earnings) is -0.47 and Price to Sales (PS) ratio is 60.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BTAI PE ratio will change depending on the future growth rate expectations of investors.